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Abstract
Background: The glial glutamate transporter GLT-1 is abundantly expressed in astrocytes and is
crucial for glutamate removal from the synaptic cleft. Decreases in glutamate uptake activity and
expression of spinal glutamate transporters are reported in animal models of pathological pain.
However, the lack of available specific inhibitors and/or activators for GLT-1 makes it difficult to
determine the roles of spinal GLT-1 in inflammatory and neuropathic pain. In this study, we
examined the effect of gene transfer of GLT-1 into the spinal cord with recombinant adenoviruses
on the inflammatory and neuropathic pain in rats.
Results: Intraspinal infusion of adenoviral vectors expressing the GLT-1 gene increased GLT-1
expression in the spinal cord 2–21 days after the infusion. Transgene expression was primarily
localized to astrocytes. The spinal GLT-1 gene transfer had no effect on acute mechanical and
thermal nociceptive responses in naive rats, whereas it significantly reduced the inflammatory
mechanical hyperalgesia induced by hindlimb intraplantar injection of carrageenan/kaolin. Spinal
GLT-1 gene transfer 7 days before partial sciatic nerve ligation recovered the extent of the spinal
GLT-1 expression in the membrane fraction that was decreased following the nerve ligation, and
prevented the induction of tactile allodynia. However, the partial sciatic nerve ligation-induced
allodynia was not reversed when the adenoviruses were infused 7 or 14 days after the nerve
ligation.
Conclusion: These results suggest that overexpression of GLT-1 on astrocytes in the spinal cord
by recombinant adenoviruses attenuates the induction, but not maintenance, of inflammatory and
neuropathic pain, probably by preventing the induction of central sensitization, without affecting
acute pain sensation. Upregulation or functional enhancement of spinal GLT-1 could be a novel
strategy for the prevention of pathological pain.
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Glutamate is the major excitatory neurotransmitter in the
mammalian central nervous system. The spinal glutama-
tergic system plays a key role in normal pain transmission
and in the induction of central sensitization, the neuronal
plasticity underlying pathological pain at the spinal level.
Glutamate release in the spinal dorsal horn is elicited fol-
lowing peripheral inflammation or nerve injury [1-5].
Excessive and prolonged stimulation of glutamate recep-
tors, including N-methyl-D-aspartate (NMDA), α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate,
and metabotropic glutamate receptors, in the spinal dor-
sal horn neurons triggers the development of the central
sensitization that generates and maintains inflammatory
and neuropathic pain [6-8].
Extracellular glutamate released from nerve terminals is
removed from the synaptic cleft via high-affinity, Na+-
dependent glutamate transporters that surround excita-
tory synapses. This removal maintains the extracellular
glutamate concentration in the physiological range, pre-
venting the glutamate overexcitation and neurotoxicity
that can occur under a variety of pathological conditions
and modulating glutamate-mediated neuronal plasticity
[9-11]. To date, five subtypes of glutamate transporters
(excitatory amino acid transporters; EAATs) have been
cloned and characterized in neurons (EAAC1/EAAT3,
EAAT4, and EAAT5) and glial cells (GLT-1/EAAT2 and
GLAST/EAAT1). Among these five subtypes, GLT-1
enriched in astrocytic processes appears to be the most
abundant EAAT and may represent the predominant route
for clearance of extracellular glutamate in the spinal cord
[11]. Furthermore, astrocytes are able to specifically
metabolize incorporated glutamate into glutamine with
the enzyme glutamine synthetase [10]. The altered expres-
sion and function of glutamate transporters modulate
glutamatergic signal transmission [9,12] and neuronal
plasticity-based events such as long-term potentiation
[13,14]. Indeed, the altered expression of glutamate trans-
porters and altered glutamate uptake activity have been
associated with neurodegenerative diseases, such as
amyotrophic lateral sclerosis, epilepsy, and stroke [11,15-
17]. In addition, several lines of evidence suggest that
glutamate transporters have important roles in pathologi-
cal pain [18]. Downregulation or functional deficiency of
glutamate transporters in the spinal dorsal horn are asso-
ciated with neuropathic pain following chronic constric-
tion nerve injury [5,19,20], spinal nerve ligation [21] and
spinal nerve transection [22], and hyperalgesia produced
by paclitaxel (taxol), which is used for chemotherapy in
cancer patients [23,24]. Pharmacological inhibition of
glutamate transporters in the spinal cord leads to sponta-
neous nociceptive behaviors and hyperalgesia to mechan-
ical and thermal nociceptive stimuli [25,26] by facilitating
spinal glutamatergic synaptic activity [27]. In addition,
riluzole, which increases glutamate uptake activity [28],
attenuates neuropathic pain following chronic constric-
tion nerve injury [19]. However, the lack of specific inhib-
itors and/or activators for glutamate transporter subtypes
makes it difficult to determine the roles and subtypes of
spinal glutamate transporters in pathological pain.
We previously constructed a recombinant adenovirus,
termed Ad-GLT-1, to deliver the GLT-1 gene in vitro and in
vivo [29,30]. In this study, to elucidate the role of a glial
glutamate transporter, GLT-1, in the pathological pain, we
examined the effect of recombinant adenovirus-mediated
gene transfer of GLT-1 into the spinal cord on inflamma-
tory and neuropathic pain in rats.
Results
Recombinant adenovirus-mediated GLT-1 expression in 
the spinal cord
We first infused control adenoviruses, Ad-EGFP, into the
spinal cord, which delivered the enhanced green fluores-
cence protein (EGFP) gene. Seven days after the intraspi-
nal infusion of Ad-EGFP, fluorescence from EGFP
expression was observed in the injected side of the dorsal
horn and a part of the ventral horn of the spinal cord, with
some transgene expression appearing within motor neu-
rons (Fig. 1A). The infusion of adenoviruses was accom-
panied by minimal tissue damage and gliosis in the spinal
cord, similar to that produced by infusion of phosphate-
buffered saline (PBS; data not shown). In a Western blot,
although immunoreactivities for endogenous GLT-1 were
observed in the L4-L6 spinal cord, the expression of GLT-
1 in the spinal cord was increased by intraspinal infusion
of Ad-GLT-1, which delivered the GLT-1 gene (Fig. 1B).
The significant increases in GLT-1 expression were
observed between 2 and 21 days (F = 8.79, P < 0.001),
which peaked between 2 and 14 days after the adenoviral
infusion.
To examine the cell types that expressed the transgene, the
sections from animals infused intraspinally with Ad-EGFP
were immunostained with glial fibrillary acidic protein
(GFAP), a marker of astrocytes, OX-42, a marker of micro-
glia, or neuronal nuclei (NeuN), a marker of neurons.
Throughout the dorsal horn of spinal cord, transgene
expression was primarily localized to GFAP-positive astro-
cytes within the white and gray matter (Fig. 1C). A part of
transgene expression was observed in OX-42-positive
microglia (Fig. 1D), but not in NeuN-positive neurons
(Fig. 1E). In the ventral horn, transgene expression was
observed in motor neurons (Fig. 1F).
Effects of spinal gene transfer of GLT-1 on acute 
nociceptive responses
We examined the effects of PBS, Ad-EGFP, and Ad-GLT-1
on the acute mechanical and thermal nociceptivePage 2 of 13
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sion. Intraspinal infusion of adenoviruses produced no
apparent behavioral abnormalities and abnormal gait. In
the paw pressure test, there was no significant difference
in the mechanical nociceptive threshold among the
groups infused intraspinally with PBS, Ad-EGFP, and Ad-
GLT-1 (F = 2.04, P = 0.147; Fig. 2A). Similarly, there were
no significant differences in the thermal nociceptive
latency in the hot plate test (Fig. 2B) between the three
groups at 52°C (F = 1.00, P = 0.379), 55°C (F = 0.40, P =
0.674), or 57°C (F = 0.60, P = 0.552).
Effect of spinal gene transfer of GLT-1 on inflammatory 
hyperalgesia
We next infused PBS, Ad-EGFP, or Ad-GLT-1 into the spi-
nal cord 7 days before intraplantar (i.pl.) injection of car-
rageenan/kaolin and examined the effect on
inflammatory mechanical hyperalgesia in the paw pres-
sure test (Fig. 3). In the animals that received an intraspi-
nal infusion of PBS, i.pl. injection of carrageenan/kaolin
decreased the mechanical nociceptive threshold of the
ipsilateral hindpaw, which was maximal at 3–4 hours and
diminished within 24 hours after the injection (Fig. 3A).
The i.pl. carrageenan/kaolin did not change the mechani-
cal nociceptive threshold of the contralateral hindpaw in
the PBS group (Fig. 3B). Intraspinal infusion of Ad-EGFP
also did not change the mechanical hyperalgesia in the
ipsilateral paw in response to carrageenan/kaolin, similar
to the group infused with PBS, but intraspinal infusion of
Ad-GLT-1 significantly reduced the hyperalgesia com-
pared with the groups infused with PBS and Ad-EGFP
(F2,144 = 10.6, P < 0.001). Neither Ad-EGFP nor Ad-GLT-1
changed the mechanical nociceptive threshold in the con-
tralateral paw compared with the group infused with PBS
(F2,144 = 2.29, P = 0.105).
Effect of spinal gene transfer of GLT-1 on neuropathic 
pain
To investigate the effect of spinal gene transfer of GLT-1
on the induction of neuropathic pain following partial
sciatic nerve ligation (pSNL), we performed pSNL 7 days
after the intraspinal infusion of the adenoviruses (Fig. 4).
In the animals that received PBS, pSNL decreased the 50%
withdrawal threshold of the ipsilateral hindpaw to tactile
stimulation with von Frey filaments, a decrease that lasted
for at least 21 days. The contralateral hindpaw also
showed substantial tactile allodynia, although it was
weaker than that in the ipsilateral hindpaw. Intraspinal
infusion of Ad-EGFP did not change the tactile allodynia
in the ipsilateral and contralateral hindpaw, which was
similar to that in the group infused with PBS. In the group
infused with Ad-GLT-1, the pSNL-induced tactile allody-
nia was completely prevented, a significant change from
the results in the PBS- and Ad-EGFP-infused groups (F2,168
= 35.1, P < 0.001). Intraspinal infusion of Ad-GLT-1 sim-
GLT-1 and EGFP expression from recombinant adenoviruses in the spinal cordFigure 1
GLT-1 and EGFP expression from recombinant ade-
noviruses in the spinal cord. A) Representative fluores-
cence photomicrograph in the spinal cord 7 days after 
intraspinal infusion of Ad-EGFP. The asterisk indicates the 
infusion site. Scale bar = 300 μm. B, C) Western blot for 
GLT-1 in the ipsilateral spinal cord from rats 2, 7, 14 and 21 
days after intraspinal infusions of Ad-GLT-1. B) Representa-
tive immunoblots show GLT-1 and actin immunoreactivity. 
C) Quantification of GLT-1 immunoreactivity. The signals 
were calculated by summing the monomer and multimer 
GLT-1 immunoreactivities. GLT-1 levels were normalized 
against the corresponding actin levels. The data present the 
means ± S.E.M. and are expressed as a percentage of the 
control (no intraspinal infusion). *P < 0.05, **P < 0.01, ***P < 
0.001 vs control, n = 4. D, E, F) Immunofluorescence labelling 
of GFAP (D; red), a marker of astrocytes; OX-42 (E; red), a 
marker of microglia; and NeuN (F; red), a marker of neu-
rons, with EGFP fluorescence (green) in the spinal cord 7 
days after intraspinal infusion of Ad-EGFP. Most EGFP-posi-
tive cells are double-labelled (yellow) with GFAP. Some 
EGFP-positive cells are double-labelled with OX-42, but not 
with NeuN. Scale bar = 50 μm.Page 3 of 13
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in the contralateral hindpaw (F2,168 = 9.96, P < 0.001). The
GLT-1 expression in the total and membrane fractions
obtained from ipsilateral spinal cord was examined by
Western blot (Fig. 5). In the animals infused with Ad-
EGFP, total amount of GLT-1 protein was not changed,
while the GLT-1 level in the membrane fraction decreased
at 7 days following pSNL (14 days after intraspinal infu-
sion). Intraspinal infusion of Ad-GLT-1 to pSNL-treated
animals increased the GLT-1 expression in the total and
membrane fractions. The recovery of the extent of GLT-1
expression was significant, compared with pSNL-treated
animals infused with Ad-EGFP.
Finally, to investigate the effect of spinal gene transfer of
GLT-1 on the maintenance of neuropathic pain, we
intraspinally infused PBS or recombinant adenoviruses 7
or 14 days after pSNL (Fig. 6). However, intraspinal infu-
sion of Ad-GLT-1 had no effect on the established tactile
allodynia in the ipsilateral hindpaw at 7 or 14 days fol-
lowing pSNL, compared with the PBS- and Ad-EGFP-
infused groups (F2,70 = 0.29, P = 0.750 and F2,91 = 1.73, P
= 0.183, respectively).
Discussion
We previously reported that an infusion of Ad-GLT-1 into
specific brain areas efficiently increased GLT-1 expression
at 2 and 5 days, and this expression remained stable up to
8 days after the infusion [29,30]. In the present study, we
confirmed that intraspinal infusion of the recombinant
adenovirus successfully transferred the GLT-1 gene into
the spinal cord surrounding the infusion site between 2
and 21 days. Our previous finding showed that infusion
of the recombinant adenovirus was accompanied by min-
imal tissue damage and had no effect on the immunore-
activity of GFAP surrounding the infusion site [29,30],
suggesting that no toxicity or gliosis resulted from the ade-
noviral infection. Although an adenovirus transferred the
LacZ gene efficiently into both neurons and glial cells
[31], the majority of cells with adenovirus-mediated gene
transfer in the dorsal horn were astrocytes when the aden-
oviruses were infused into the spinal cord, consistent with
previous reports [32]. Because GLT-1 is expressed mainly
in astrocytes, the adenovirus-mediated expression system
seemed likely to be suitable for the present study. In the
ventral horn, the transgene expression was observed in
astrocytes and motor neurons. Of all the neurons within
the spinal cord, motor neurons have been shown to effi-
ciently uptake and express recombinant adenoviruses
[32,33]. Although we did not determine the influence of
GLT-1 gene transfer in motor neurons in this study, at
least, it did not induce behavioral abnormalities and
abnormal gait, and had no effect on the escape behaviors
from the mechanical and thermal nociceptive stimuli.
Using the recombinant adenoviruses, we showed that
gene transfer of GLT-1 into the spinal cord had no effect
on the acute nociceptive responses to mechanical and
Effects of spinal GLT-1 gene transfer on the acute mechanical and thermal nociceptive responses in naive ratsFigure 2
Effects of spinal GLT-1 gene transfer on the acute mechanical and thermal nociceptive responses in naive rats. 
Seven days after an intraspinal infusion of PBS (open bars), Ad-EGFP (hatched bars), or Ad-GLT-1 (closed bars), the mechanical 
nociceptive threshold (g) was measured in naive rats using the paw pressure test (A) and thermal nociceptive latency (sec) to 
52, 55 and 57°C was measured using the hot plate test (B). Data are presented as the mean ± S.E.M., n = 12.Page 4 of 13
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Effect of spinal GLT-1 gene transfer on mechanical inflammatory hyperalgesiaFigure 3
Effect of spinal GLT-1 gene transfer on mechanical inflammatory hyperalgesia. Seven days after an intraspinal infu-
sion of PBS (open circle), Ad-EGFP (open square), or Ad-GLT-1 (closed square), the mechanical nociceptive thresholds of the 
ipsilateral (A) and contralateral (B) paws were measured in the paw pressure test following i.pl. injection of 2% carrageenan/
kaolin at time 0. Data are presented as the mean ± S.E.M., *P < 0.05 vs PBS, #P < 0.05 vs Ad-EGFP, n = 6–8.
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Effect of spinal GLT-1 gene transfer on the induction of allodynia in the pSNL-induced neuropathic pain modelFigure 4
Effect of spinal GLT-1 gene transfer on the induction of allodynia in the pSNL-induced neuropathic pain model. 
PBS (open circle), Ad-EGFP (open square), or Ad-GLT-1 (closed square) was infused intraspinally (arrows in the graph). Seven 
days later (day 0), pSNL was performed (arrows) and 50% withdrawal thresholds of the ipsilateral (A) and contralateral (B) 
paws were measured with the von Frey filament test on the indicated days. Data are presented as the mean ± S.E.M. *P < 0.05, 
***P < 0.001 vs PBS; #P < 0.05, ###P < 0.001 vs Ad-EGFP, n = 6–9.
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previous studies using glutamate transporter activators
such as MS-153 [34] and riluzole [4,19]. In contrast,
intrathecal injection of glutamate transporter inhibitors
into naive animals elevates the spinal extracellular gluta-
mate level and produces spontaneous nociceptive behav-
iors and hyperalgesia [25-27]. These results suggest that
maintaining a low extracellular glutamate level following
an increase in spinal GLT-1 protein does not affect acute
spinal pain transmission under normal conditions. In
addition, the important finding in this experiment is to
show no evidence that adenoviral infection in the spinal
cord influenced the basal nociceptive threshold.
Here we showed that spinal gene transfer of GLT-1
reduced i.pl. carrageenan/kaolin-induced inflammatory
mechanical hyperalgesia and pSNL-induced tactile allody-
nia, when the spinal infusion of the adenoviruses was per-
formed 7 days before i.pl. injection of carrageenan/kaolin
and pSNL surgery, respectively. Furthermore, it recovered
the extent of the spinal GLT-1 expression in the mem-
brane fraction that was decreased at 7 days following
pSNL. These results suggest that adenovirus-mediated
overexpression of GLT-1 in the spinal cord prevents the
induction of inflammatory and neuropathic pain. Con-
sistent with the present data, riluzole, which reduces extra-
cellular glutamate by activating glutamate transporters
[28], inhibits the induction of inflammatory and neuro-
pathic pain [4,19]. Glutamate release from primary affer-
ent neurons in the spinal dorsal horn is enhanced by
peripheral inflammation and nerve injury [1-5]. Excessive
and prolonged activation of spinal glutamate receptors
and subsequent intracellular adaptation in the postsynap-
tic dorsal horn neurons lead to a prolonged increase in
neuronal excitability, called central sensitization, which
produces pathological pain [7,8]. Indeed, inhibition of
glutamate release by anticonvulsant agents attenuates the
induction of hyperalgesia following peripheral inflamma-
tion or nerve injury [4,35]. Our results suggest that the
increase of glutamate uptake activity following overex-
pression of spinal GLT-1 protein decreases the excessive
extracellular glutamate level; this in turn inhibits the gen-
eration of neuronal plasticity related to central sensitiza-
tion following peripheral inflammation and nerve injury.
In the present pSNL model, tactile allodynia was pro-
duced also in the contralateral to the nerve injury site,
called mirror-image pain. It is considered that mirror-
image pain arises from altered contralateral spinal
processing of incoming sensory information [36]. The
present study showed that contralateral allodynia was also
prevented by the unilateral gene transfer of GLT-1 into the
ipsilateral spinal cord, although the unilateral gene trans-
fer did not spread to the contralateral spinal cord. Milli-
gan et al. demonstrated that mirror-image pain may be
due to spinal glial activation and release of proinflamma-
tory cytokines, which may spread and reach the contralat-
eral spinal cord to generate sensitization of the
contralateral dorsal horn neurons [37]. The spinal glial
activation following peripheral nerve injury is dependent
on spinal NMDA receptor activation [38,39]. Conse-
quently, it is conceivable that the ipsilateral gene transfer
of GLT-1 may attenuate the activation of glial cells and the
release of proinflammatory cytokines in the ipsilateral spi-
nal cord by inhibiting a glutamate-dependent pathway,
which has the effect of preventing the induction of sensi-
Effect of spinal GLT-1 gene transfer on the spinal GLT-1 expression in the total a d membrane fraction followingpSNLFigure 5
Effect of spinal GLT-1 gene transfer on the spinal 
GLT-1 expression in the total and membrane frac-
tion following pSNL. Seven days after Ad-EGFP or Ad-
GLT-1 was infused intraspinally, pSNL or sham surgery was 
performed. Seven days later (14 days after the intraspinal 
infusion), the GLT-1 expression in the total (A, B) and mem-
brane (C, D) fractions obtained from ipsilateral spinal cord 
was assessed by Western blot. A, C) Representative immu-
noblots show GLT-1 and actin immunoreactivity in total and 
membrane fractions. No actin band was observed in the 
membrane fraction. B, D) Quantification of GLT-1 immuno-
reactivity in the total and membrane fractions. The signals 
were calculated by summing the monomer and multimer 
GLT-1 immunoreactivities. Total GLT-1 levels were normal-
ized against the corresponding actin levels. The data present 
the means ± S.E.M. and are expressed as a percentage of the 
control (intraspinal infusion of Ad-EGFP and sham surgery) 
for each fraction. *P < 0.05, n = 3–4.Page 7 of 13
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Effect of spinal GLT-1 gene transfer on the maintenance of allodynia in the pSNL-induced neuropathic pain modelFigure 6
Effect of spinal GLT-1 gene transfer on the maintenance of allodynia in the pSNL-induced neuropathic pain 
model. PBS (open circle), Ad-EGFP (open square), or Ad-GLT-1 (closed square) was intraspinally infused 7 (A) or 14 (B) days 
after pSNL (arrows in the graph). 50% withdrawal thresholds of ipsilateral paw were measured with the von Frey filament test 
on the indicated days following pSNL at day 0. Data are presented as the mean ± S.E.M., n = 4–6.
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neurons.
In contrast to the ability of exogenous GLT-1 to prevent
the induction of pathological pain, when the spinal infu-
sion of the adenoviruses was performed 7 or 14 days after
pSNL, spinal gene transfer of GLT-1 did not reverse the
established allodynia. Many previous studies have shown
that the expression of GLT-1 and glutamate uptake activity
are decreased 7–14 days after nerve injury [5,19,20,22].
Similarly, we found a decrease in GLT-1 expression in the
membrane fraction of the spinal cord at 7 days following
pSNL, although the total amount of GLT-1 protein was
not changed in the present pSNL-induced neuropathic
pain model in contrast to previous reports using other
neuropathic pain models [19,22]. The spinal glutamater-
gic system contributes to not only the induction of patho-
logical pain, but also to its maintenance [6,40,41]. Sung et
al. reported that riluzole twice daily for 4 days beginning
on postoperative day 5 gradually reversed the mainte-
nance of thermal hyperalgesia and mechanical allodynia
after chronic constriction nerve injury [19]. However, rilu-
zole has multiple actions in addition to activating gluta-
mate transporters, including blockade of sodium channel
α-subunits, glutamate receptors, and γ-aminobutyric acid
uptake and the stabilization of voltage-gated ion channels
[42]. The inhibitory effect of riluzole on the maintenance
of neuropathic pain may therefore be due to actions other
than the activation of glutamate transporters. Our present
findings suggest that the expression of GLT-1 in the spinal
cord plays little role in the maintenance of neuropathic
pain, at least in the present conditions. Otherwise, the
expression of other EAAT subtypes, GLAST and EAAC1,
was also decreased in the spinal cord of neuropathic pain
model animals [19,20,22-24]. Reduction of glutamate
uptake activity via GLAST and EAAC1 may contribute to
the maintenance of neuropathic pain.
An accumulating amount of evidence suggests that spinal
astrocytes, as well as microglia, contribute to pathological
pain [43,44]. Early studies indicated that spinal astrocytes
are activated in diverse models of pathological pain
[37,45,46], and blocking the activation and function of
spinal astrocytes prevents and reverses hyperalgesia and
allodynia [37,47,48]. Because GLT-1 is expressed mainly
in astrocytes, the present findings may further support the
importance of spinal astrocytes in pathological pain.
Conclusion
The present study showed that recombinant adenovirus-
mediated gene transfer of GLT-1 into the spinal cord
reduces the induction of inflammatory and neuropathic
pain without affecting basal nociceptive responses. These
findings support the idea that altered expression or func-
tion of GLT-1 in the spinal cord contributes to the patho-
genesis of inflammatory and neuropathic pain. Therefore,
upregulation or functional enhancement of spinal GLT-1
may prevent the induction and progression of pathologi-
cal pain. Glutamate receptor antagonists are effective in
reducing pathological pain in animal models and clinical
settings, but their usefulness is limited by adverse side-
effects [49]. Further studies to delineate the roles of spinal
glutamate transporters in pathological pain states might




Male Sprague-Dawley rats initially weighting 180–220 g
were used. They were kept at a constant ambient temper-
ature of 24 ± 1°C under a 12-hr light/dark cycle and pro-
vided free access to food and water. The rats were
individually housed in plastic cages with wood-chip bed-
ding for at least 1 day before surgery. All experimental pro-
cedures were approved by the Kyoto University Animal
Experimentation Committee and complied with the rec-
ommendations of the International Association for the
Study of Pain [50].
Construction of recombinant adenoviruses
Construction of the recombinant adenoviruses was
described previously [29]. Briefly, fragments of rat GLT-1
and EGFP cDNAs were subcloned, respectively, into mul-
tiple cloning sites 1 and 2 of the vector pIRES (Clontech,
Palo Alto, CA, USA). A 3.5-kb fragment containing the
GLT-1-internal ribosome entry site-EGFP sequence was
then subcloned into the cosmid vector pAxCAwt (Takara,
Kyoto, Japan), which contains the CAG promoter
(cytomegalovirus enhancer and β-actin promoter) and
the rabbit β-globin polyadenylation signal [51]. For the
control adenovirus, only the EGFP fragment was sub-
cloned into pAxCAwt. The recombinant adenoviruses
were generated using an Adenovirus Expression Vector kit
(Takara) according to the manufacturer's instructions and
named Ad-GLT-1 and Ad-EGFP. They were propagated in
HEK293 cells and purified using the Viraprep Adenovirus
Purification Kit (Virapur, San Diego, CA). The titers of Ad-
GLT-1 and Ad-EGFP were 5.6 × 108 to 1.0 × 1010 plaque-
forming units/ml.
Intraspinal infusions of recombinant adenoviruses
Infusions of the recombinant adenoviruses into the spinal
cord were performed as reported previously [32]. Briefly,
animals that were anesthetized with pentobarbital
sodium (50 mg/kg, i.p.) underwent hemilaminectomies
at the L1-L4 vertebral segments. Intraspinal infusion was
performed unilaterally on the right side. After exposure of
the spinal cord, each animal received four injections (0.4
μl; 0.8 mm apart and 0.5 mm deep) of PBS or individual
adenoviral vectors along the L4-L5 dorsal root entry zonePage 9 of 13
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tip of glass micropipette reached lamina IV-VI of the spi-
nal cord. The dorsal muscle and skin were then sutured.
The animals were placed on a 37°C heat pad and moni-
tored continually until recovery from the effects of the
anesthetic.
Tissue preparation and Western blot
Animals were rapidly sacrificed by decapitation. The L4-
L6 lumber spinal cord was rapidly removed, and cut into
a left and right half from the ventral midline. Then, the
right lumbar spinal cord segments were immediately fro-
zen in liquid nitrogen and stored at -80°C until use. The
segments were homogenized with a polytron homoge-
nizer in ice-cold 20 mM Tris buffer (pH 7.5) containing
0.32 M sucrose, 2 mM ethylenediaminetetraacetic acid
(EDTA), 0.5 mM ethyleneglycol-bis (β-aminoethyl)-
N,N,N',N'-tetraacetic acid (EGTA) and a cocktail of pro-
tease inhibitors (Calbiochem, San Diego, CA). Some of
the homogenate was separated and saved for western blot
as total fraction. Remains were centrifuged (1,000 × g, 5
min, 4°C) to remove nuclear debris. The resulting super-
natants were centrifuged (18,000 × g, 30 min, 4°C) to
obtain the synaptosomal pellet. The synaptosomal pellets
were resuspended in ice cold water containing p a cocktail
of protease inhibitors to lyse the synaptosomal mem-
branes for 45 min on ice. The lysed synaptosomal sample
was centrifuged (40,000 × g, 15 min, 4°C) to pellet synap-
tosomal membranes, which was then resuspended in 20
mM Tris buffer (pH 7.4) containing 2 mM EDTA, 0.5 mM
EGTA, 1% Triton X-100 and a cocktail of protease inhibi-
tors, and saved for western blot (membrane fraction). The
protein concentrations were measured. Samples were
stored at -20°C until the Western blot analysis.
Aliquots of protein sample (2 μg) prepared from total or
membrane fractions were diluted with an equal volume of
sample buffer (124 mM Tris-HCl (pH 7.5), 4% sodium
dodecyl sulphate (SDS), 10% glycerol, 4% 2-mercap-
toethanol and 0.02% bromophenol blue), subjected to
SDS-polyacrylamide gel electrophoresis, and electropho-
retically transferred onto polyvinylidene fluoride mem-
branes (Millipore, Bedford, MA). Blots were blocked for 1
hr with 10% blocking reagent (Blocking-One, Nacalai
tesque, Kyoto, Japan) in Tris-buffered saline (pH 7.5) con-
taining 0.1% Tween-20, and then incubated with goat
anti-GLT-1 (1:2,000; Santa Cruz Biotechnology, Santa
Cruz, CA) and goat anti-actin (1:20,000; Santa Cruz Bio-
technology) for 1 hr at room temperature. Then, the blots
were incubated with horseradish peroxidase-conjugated
donkey anti-goat IgG (1:25,000, Jackson ImmunoRe-
search Laboratories, West Grove, PA) for 1 hr at room
temperature. The immunoreactive proteins were detected
with an enhanced chemiluminescence kit (Amersham
Biosciences) according to the manufacturer's instructions,
and visualized by exposure to X-ray film. For the quantifi-
cation of Western signals, the signal for each lane was cal-
culated by summing the (area × [density-background])
measurement for the monomer and multimer GLT-1
bands with a computer-assisted imaging analysis system
(Image J 1.39).
Histology and immunohistochemistry
Animals were deeply anesthetized with sodium pentobar-
bital (50 mg/kg, intraperitoneally) and perfused transcar-
dially through the ascending aorta with 0.1 M PBS (pH
7.4), immediately followed by 4% paraformaldehyde in
0.1 M phosphate buffer. The L4-L6 lumbar spinal cord
was removed, post-fixed in the same fixative for 3 hr, cry-
oprotected with 15% sucrose in 0.1 M phosphate buffer
overnight at 4°C, and then frozen in liquid nitrogen.
Coronal sections (30 μm) were thaw-mounted onto MAS
coat slide glasses (Matsunami, Osaka, Japan).
For histological examination of EGFP fluorescence, each
section was examined by fluorescent microscopy for
EGFP. For immunohistochemical examination of cell
markers with EGFP fluorescence, the sections were gently
washed three times (10 min each) in PBS, and then per-
meabilized and blocked at room temperature for 1 hr in
4% normal goat serum in PBS containing 0.1% Triton X-
100. For immunofluorescence imaging of the marker pro-
teins for neurons, astrocyte and microglia, spinal the spi-
nal sections were incubated overnight at 4°C with mouse
anti-NeuN (1:100, Chemicon, Temecula, CA), mouse
anti-GFAP (1:100, Sigma, St. Louis, MO) or mouse anti-
OX-42 (1:100, Serotic, Ltd., Oxford, UK) monoclonal
antibody in PBS containing 0.1% Triton X-100 and 4%
normal goat serum. The sections were washed three times
in PBS, and incubated with Alexa Fluoro 568-labeled goat
anti-mouse IgG antibody (1:200; Molecular Probes) in
PBS with 0.1% Triton X-100 and 4% normal goat serum
for 1 hr at room temperature. Images were constructed by
measuring the fluorescence signal using a Nikon Diaphot
200 microscope equipped with a laser scanning confocal
imaging system (MRC-1024 system; Bio-Rad Laborato-
ries, Hercules, CA) with excitation lines of 488 and 568
nm.
Inflammatory and neuropathic pain models
Inflammatory pain model
Acute inflammation was produced by subcutaneous injec-
tion with a mixture of 2% λ-carrageenan and 2% kaolin
dissolved in saline (0.1 ml) into the plantar region of the
right hind paw, as previously described [52].
Neuropathic pain model
pSNL, a well-characterized rat model of neuropathic pain,
was performed as previously described [53]. Briefly, under
diethylether anesthesia, a skin incision was made, and thePage 10 of 13
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leading to the posterior biceps femoris/semitendinosus
muscles. The 1/3–1/2 dorsal section of the sciatic nerve
was ligated tightly with 7-0 silk suture. The wound was
closed by suturing the muscle and skin layers. After recov-
ering from the anesthesia, almost all animals showed
guarding of the hind paw, but none engaged in autotomy.
Behavioral tests
Hot plate test
Thermal nociception was evaluated by the hot plate test
using a hot plate analgesy meter (Ugo Basile, Milan, Italy).
The animal was placed on a plate heated to 52, 55, or
57°C and the latency to licking a hindpaw or jumping was
measured. The cut-off time was 60 sec to prevent tissue
damage.
Paw pressure test
For assessing the mechanical nociceptive threshold, the
paw pressure test was performed using an analgesimeter
with a cuneate piston (Ugo Basile). The piston was loaded
at a rate of 16 g/sec. The pressure-elicited paw-withdrawal
behavior was determined as a nociceptive threshold. The
procedure for paw pressure testing was carried out 3 times
per day for habituation. After 2 days of habituation, the
threshold was measured following three additional habit-
uation procedures and the value was taken as a control.
Von Frey filament test
Tactile allodynia was measured by the up-down method
as described previously [54]. Animals were individually
placed on a wire mesh floor and acclimatized to the envi-
ronment for at least 30 minutes. After acclimatization, the
tactile stimulus was applied to the middle plantar surface
of the paw by placing one of a series of von Frey filaments
(0.4, 0.6. 1.4, 2.0, 4.0, 6.0, 8.0, 10.0, 15.0 g) perpendicu-
lar to the surface of the paw. The testing was initiated at
2.0 g. In the absence of a paw withdrawal response to the
initially selected filament, a stronger stimulus was pre-
sented; in the event of paw withdrawal, the next weaker
stimulus was chosen. Four additional responses were
observed after the first withdrawal response, and the 50%
withdrawal threshold was calculated [55]. In cases where
continuous positive or negative responses were observed
to the exhaustion of the stimulus set, values of 15.00 g and
0.4 g were assigned, respectively.
Statistical analysis
Data are expressed as means ± S.E.M. In the behavioral
tests and Western blot analyses, the statistical significance
was calculated using one-way and two-way analysis of var-
iance, followed by the Bonferroni post hoc test. Differences
with P < 0.05 were considered significant.
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